Results 121 to 130 of about 21,847 (205)

Targeted Therapy for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Critical Narrative Review and an Evidence-Graded Approach to Agent Selection. [PDF]

Antibodies (Basel)
Guarino L, Rizzuto G, Coppolelli V, Scipione A, Scattone M, Gargano L, Scribani Rossi P, Del Duca E, Dattola A, Pellacani G, Nisticò S, Chello C.   +11 more
europepmc   +1 more source

Infectious adverse events associated with novel Bruton tyrosine kinase (BTK) inhibitors in adults with chronic lymphocytic leukaemia: A meta-analysis of randomized controlled trials. [PDF]

Br J Haematol
Janc JJ, Wróbel T, Feliniak N, Kalicińska E.   +3 more
europepmc   +1 more source

Chronic Spontaneous Urticaria in the Era of Targeted Therapy: From Pathogenic Mechanisms to Precision Medicine. [PDF]

Pharmaceutics
Andrzejczak K, Witkowski W, Górka-Dynysiewicz J, Pawłowicz R, Kopeć A.   +4 more
europepmc   +1 more source

A functional prognostic model predicts progression-free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax. [PDF]

Hemasphere
Hermansen JU, Kong W, Brodersen AM, Yin Y, Urban A, Rein ID, He L, Agius R, Teglgaard RS, Rousu J, Brieghel C, Kersting S, Levin MD, Tran HTT, Mattsson M, Ranti J, Veldhuis GJ, da Cunha-Bang C, Mous R, Dubois J, Kater AP, Enserink JM, Niemann CU, Aittokallio T, Skånland SS.   +24 more
europepmc   +1 more source

Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fcγ receptor (FcγR) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy. [PDF]

Res Pract Thromb Haemost
Kartika T, Buitrago L, Li J, Cunningham-Rundles C, Coller BS.   +4 more
europepmc   +1 more source

Mechanisms of resistance to BTK inhibitors in B cell malignancies and emerging targeted strategies. [PDF]

Mol Ther Oncol
Ni Q, Rui L.
europepmc   +1 more source

Chronic lymphocytic leukemia management in India: balancing evidence, access, and affordability in clinical practice. [PDF]

Front Oncol
Sahni S, Rani L, Gupta R, Gogia A.
europepmc   +1 more source

Pretreatment With BTK Inhibitors Improved the Sensitivity of DLBCL Cells to CAR-T Cells in a Coculture System by Downregulating the Polarisation of M2 Macrophages. [PDF]

J Cell Mol Med
Qi Y, Fan X, Wang J, Li X, Mu J, Cui R, Deng Q.   +6 more
europepmc   +1 more source

Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cells. [PDF]

Blood Adv
Pizzarella D, Kofides A, Hatcher JM, Liu X, Guijosa A, Tsakmaklis N, Peachey AL, Wang J, Guerrera ML, Patterson CJ, Hunter ZR, Sun H, Sarosiek SR, Castillo JJ, Buhrlage SJ, Dhe-Paganon S, Branagan AR, Treon SP, Liu S.   +18 more
europepmc   +1 more source